Navigation Links
BioMarin to Present at the Deutsche Bank Healthcare Conference
Date:4/26/2011

NOVATO, Calif., April 26, 2011 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in Boston on Tuesday, May 3, 2011 at 3:30 p.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase III clinical development for the treatment of MPS IVA, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU, BMN-701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA), which is currently in Phase I/II clinical development for the treatment of Pompe disease, and BMN-673, a poly ADP-ribose polymerase (PARP) inhibitor, which is currently in Phase I/II clinical development for the treatment of genetically-defined cancers. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Investors

MediaEugenia Shen

Bob PurcellBioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.(415) 506-6570

(415) 506-3267
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin to Present at the Barclays Global Healthcare Conference
2. BioMarin to Present at the Cowen Health Care Conference
3. BioMarin to Present at the Citi Global Healthcare Conference
4. BioMarin Announces Fourth Quarter and Full Year 2010 Financial Results
5. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
6. BioMarin to Host Fourth Quarter and Full Year 2010 Financial Results
7. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
8. BioMarin Initiates Phase 1/2 Trial for BMN 673 for the Treatment of Genetically-Defined Cancers
9. BioMarin to Present at the J.P. Morgan 29th Annual Healthcare Conference
10. BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
11. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... 8, 2016 /PRNewswire/--  Cell Applications, Inc. and ... services are now available in North ... (3D) bioprinting approach called the "Kenzan Method." Utilizing ... a state-of-the-art robotic system that fabricates 3D tissue ... pay-for-service bio-printing model that makes scaffold-free tissue available ...
(Date:2/8/2016)... Feb. 8, 2016 ... of the "Label-Free Detection Market by ... 2020" report to their offering. ... addition of the "Label-Free Detection Market ... to 2020" report to their offering. ...
(Date:2/8/2016)... , Feb. 8, 2016  Astellas Pharma Inc. President and ... promotion of James Robinson as president, Americas Operations, ... in North and South America , effective ... US, representing the commercial organization in the United ... Masao Yoshida , who is retiring in ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 2016 , ... Stephanie Hebert Insurance Agency, serving families of ... charity campaign. As part of their ongoing community involvement program, funds are now ... children deserve a voice, and in the spirit of neighbors helping neighbors in ...
(Date:2/8/2016)... ... 2016 , ... Brenton Engineering , powered by Pro ... wrapped products at WestPack 2015, February 9-11, in Anaheim, California. This new solution ... or fully-automatic case packing with a small footprint, rugged, highly flexible, and cost-effective ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
(Date:2/8/2016)... ... , ... Delta Dental of California and its affiliated companies announced today that ... who recently retired as president and CEO of Delta Dental of California and its ... Year , helped lead the effort to raise funds for studies to strengthen pancreatic ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating disorders ... significant number of women and men with eating disorders report a history of ... predicts the development of an eating disorder. , At the 2016 iaedp ...
Breaking Medicine News(10 mins):